Amneal completes acquisition of Kashiv BioSciences

• Amneal completed its acquisition of Kashiv BioSciences, adding end-to-end biosimilar R&D, manufacturing, and commercialization capabilities.
• The deal creates a fully integrated biosimilars platform, positioning biosimilars as a long-term growth pillar within Amneal’s Affordable Medicines business.
• The combined business targets an expected surge in biologic loss of exclusivity, citing more than $300 billion of projected global opportunities over the next decade.
• Integration work is underway, focused on combining development and manufacturing operations while advancing the biosimilar pipeline.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amneal Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608100800PRIMZONEFULLFEED9806496) on August 10, 2026, and is solely responsible for the information contained therein.